Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941844 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
A Phase 3 study of Major Depressive Disorder, sponsored by Definium Therapeutics US.
- Active
- Registry status
- Phase 3
- Development phase
- 149
- Enrollment target
- 20
- Study locations
NCT06941844: Active Phase 3 study of Major Depressive Disorder, sponsored by Definium Therapeutics US.
NCT06941844 is a Phase 3 study of Major Depressive Disorder that is active but no longer recruiting, run by Definium Therapeutics US. The registered enrollment target is 149 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06941844, a Phase 3 study of Major Depressive Disorder, is active but no longer recruiting, sponsored by Definium Therapeutics US.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 149 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Primary Outcome
The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MM120 (LSD D-Tartrate)
Study Locations (20)
Florida
- Clinical Neuroscience Solutions, Inc - Jacksonville
- Clinical Neuroscience Solutions, Inc - Orlando
- Charter Research - Orlando
Arkansas
- Preferred Research Partner - Fayetteville
- Preferred Research Partners, Inc - Little Rock
California
- Kadima Neuropsychiatry Institute - La Jolla
- Psychedelic Science Institute - Santa Monica
Massachusetts
- Adams Clinical Boston - Boston
- Adams Clinical - Watertown
New York
- Adams Clinical Harlem - New York
- Columbia - New York State Psychiatric Institute - New York
Ohio
- Neuro-Behavioral Clinical Research - Canton
- University of Cincinnati - Cincinnati
Colorado
- Mountain View Clinical Research, Inc - Denver
Illinois
- Uptown Research - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2027-05 |
| Phase | Phase 3 |
What the registry record for NCT06941844 still lists
NCT06941844 is an interventional study that assigns participants to a tested intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06941844 names 20 study sites across 13 states, led by Florida, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT06941844 about?
NCT06941844 is a clinical study titled "A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)". A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
What is the current status of trial NCT06941844?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 149 participants. The study started on 2025-04-14. Estimated completion is 2027-05.
What conditions does trial NCT06941844 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT06941844?
The interventions under investigation include: Placebo (OTHER), MM120 (LSD D-Tartrate) (DRUG).
Who is sponsoring clinical trial NCT06941844?
This trial is sponsored by Definium Therapeutics US, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941844 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06941844's enrollment target sits among peer trials
149 100th of 282 higher than 183 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI